Author:
Guerra Angela Patricia,Olivera Mario Javier,Cortés Liliana Jazmín,Chenet Stella M.,Macedo de Oliveira Alexandre,Lucchi Naomi W.
Abstract
Abstract
Background
Resistance to anti-malarial drugs is associated with polymorphisms in target genes and surveillance for these molecular markers is important to detect the emergence of mutations associated with drug resistance and signal recovering sensitivity to anti-malarials previously used.
Methods
The presence of polymorphisms in genes associated with Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine was evaluated by Sanger sequencing, in 85 P. falciparum day of enrollment samples from a therapeutic efficacy study of artemether–lumefantrine conducted in 2018–2019 in Quibdo, Colombia. Samples were genotyped to assess mutations in pfcrt (codons 72–76), pfdhfr (codons 51, 59, 108, and 164), and pfdhps genes (codons 436, 437, 540, and 581). Further, the genetic diversity of infections using seven neutral microsatellites (NMSs) (C2M34, C3M69, Poly α, TA1, TA109, 2490, and PfPK2) was assessed.
Results
All isolates carried mutant alleles for pfcrt (K76T and N75E), and for pfdhfr (N51I and S108N), while for pfdhps, mutations were observed only for codon A437G (32/73, 43.8%). Fifty samples (58.8%) showed a complete neutral microsatellites (NMS) profile. The low mean number of alleles (2 ± 0.57) per locus and mean expected heterozygosity (0.17 ± 0.03) showed a reduced genetic diversity. NMS multilocus genotypes (MMG) were built and nine MMG were identified.
Conclusions
Overall, these findings confirm the fixation of chloroquine and pyrimethamine-resistant alleles already described in the literature, implying that these drugs are not currently appropriate for use in Colombia. In contrast, mutations in the pfdhps gene were only observed at codon 437, an indication that full resistance to sulfadoxine has not been achieved in Choco. MMGs found matched the clonal lineage E variant 1 previously reported in northwestern Colombia.
Funder
U.S. Agency for International Development (USAID) through the Latin American and the Caribbean Regional Malaria Program
Colombian National Institute of Health
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference36 articles.
1. Padilla-Rodríguez JC, Olivera MJ, Ahumada-Franco ML, Paredes-Medina AE. Malaria risk stratification in Colombia 2010 to 2019. PLoS ONE. 2021;16: e0247811.
2. WHO. World malaria report 2019. Geneva, World Health Organization, 2019. https://www.who.int/publications/i/item/world-malaria-report-2019. Accessed 3 Nov 2021.
3. WHO. World malaria report 2020. Geneva, World Health Organization, 2020. https://www.who.int/publications/i/item/9789240015791. Accessed 3 Nov 2021.
4. Ferro C, Sastoque LA. Informe del evento malaria, Colombia 2019. Instituto Nacional de Salud. http://www.ins.gov.co/buscador-eventos/Informesdeevento/MALARIA%20PE%20XIII%202019.pdf. Accessed 9 Nov 2021.
5. Osorio LE, Giraldo LE, Grajales LF, Arriaga AL, Andrade AL, Ruebush TK, et al. Assessment of therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in an area of low malaria transmission in Colombia. Am J Trop Med Hyg. 1999;61:968–72.